__________________________________________________________________________________ OXB( Oxford Biomedica)
of OXB’ s continued investment in both its clients and its overall operational efficiency, allowing the organization to provide a greater scope of end-to-end viral vector capabilities and deliver more flexible solutions worldwide.
“ From an R & D perspective, we are a quality and innovation-led company. We’ re really focused on what our clients are really looking for and how we can produce a quality vector in a quality format. We have our own innovation department within the organization that focuses solely on cutting-edge technology and applying it internally for different endpoints, evaluating how we can make our process more robust and streamlined and boost our productivity,” Mark elucidates.
“ From that perspective, we look at various parts across the industry to see what we can leverage, whilst also attending
manufacturing-today. com 45